Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2

Blazej Dolniak1, Efstratios Katsoulidis, Nathalie Carayol

  • 1Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Department of Medicine, Northwestern University Medical School, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60611, USA.

Insights

Arsenic trioxide activates MAPK signal-integrating kinases (Mnks) 1 and 2, which negatively regulate its cancer-killing effects. Inhibiting Mnk kinases enhances arsenic trioxide

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Arsenic trioxide (As(2)O(3)) induces apoptosis in malignant cells, but its precise mechanisms remain unclear.
  • Understanding As(2)O(3) signaling pathways is crucial for developing targeted leukemia therapies.

Purpose of the Study:

  • To elucidate the role of MAPK signal-integrating kinases (Mnks) 1 and 2 in arsenic trioxide-induced apoptosis.
  • To investigate the upstream regulation of Mnk activation by the p38 MAPK pathway.

Main Methods:

  • Utilized leukemia cell lines with targeted gene disruptions for p38alpha MAPK, Mnk1, and Mnk2.
  • Assessed Mnk activation and downstream substrate phosphorylation (eIF4E at Ser-209) following As(2)O(3) treatment.
  • Examined the impact of Mnk disruption and pharmacological inhibition on As(2)O(3)-induced apoptosis in primary leukemic progenitors.

Main Results:

  • As(2)O(3) activates Mnk1 and Mnk2 in a p38 MAPK-dependent manner.
  • Activated Mnks phosphorylate eukaryotic initiation factor 4E (eIF4E) at Ser-209.
  • Disruption of Mnk genes enhances As(2)O(3)-induced apoptosis, indicating a negative feedback role for Mnks.

Conclusions:

  • Mnk kinases act as negative regulators of As(2)O(3)-induced apoptosis and antileukemic responses.
  • Pharmacological inhibition of Mnk activity potentiates As(2)O(3)'s therapeutic effects on acute leukemia cells.
  • Targeting the Mnk pathway offers a potential strategy to improve As(2)O(3) efficacy in cancer treatment.

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...